FDA Renews Dermatologic/Ophthalmic Drugs Panel Charter
Federal Register notice: FDA has renewed the charter of its Dermatologic and Ophthalmic Drugs Advisory Committee for an additional two years. The new charter will be in effect until 10/7/2020. To view the notice, click here.